Next Article in Journal
Biosynthesized Silver Selenide Nanoparticles from Meyerozyma guilliermondii as a Novel Adjuvant to Revolutionize Gentamicin Therapy
Previous Article in Journal
Seven Years of Salmonella: Changing Resistance and Clinical Insights
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Transfer and Fitness of ISAba52-Mediated tet(X3) Transposon in Acinetobacter spp.

1
Joint International Research Laboratory of Agriculture and Agri-Product Safety, Ministry of Education of China, Institutes of Agricultural Science and Technology Development, Yangzhou University, Yangzhou 225009, China
2
Jiangsu Key Laboratory of Zoonosis, Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China
3
Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, Ministry of Agriculture of China, Yangzhou University, Yangzhou 225009, China
4
College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China
*
Author to whom correspondence should be addressed.
Microorganisms 2025, 13(12), 2656; https://doi.org/10.3390/microorganisms13122656 (registering DOI)
Submission received: 9 October 2025 / Revised: 13 November 2025 / Accepted: 20 November 2025 / Published: 22 November 2025
(This article belongs to the Section Antimicrobial Agents and Resistance)

Abstract

The global spread of tigecycline resistance conferred by tet(X3) poses a serious threat to clinical treatment of multidrug-resistant (MDR) Acinetobacter infections. Despite tet(X3) being detected in diverse Acinetobacter species, its transposition mechanism and fitness in these pathogens remain poorly characterized. Here, we reported the first plasmid-borne ISAba52-mediated transposable element harboring tet(X3) in Acinetobacter amyesii YH16040. Conjugation experiments demonstrated the transferability of tet(X3) into the chromosome of Acinetobacter baylyi ADP1 at an efficiency of (7.1 ± 2.5) × 10−8. High-throughput sequencing revealed six tandem copies of ISAba52-flanked tet(X3), floR, and sul2 forming a 231.6 Kb complex transposon in the obtained transconjugant A. baylyi YH16040C. Phenotypic assays showed that YH16040C exhibited elevated resistance to tigecycline, chlortetracycline, florfenicol, and trimethoprim-sulfamethoxazole by 64- to 256-fold. Notably, YH16040C exhibited a growth advantage, reduced competition ability, and non-significant difference in biofilm formation compared to ADP1 in antibiotic-free backgrounds. Under moderate antibiotic treatment of tigecycline, chlortetracycline, florfenicol, and trimethoprim-sulfamethoxazole, the competition ability of YH16040C against ADP1 was significantly higher than that without antibiotics. All of these highlight the importance of ISAba52-mediated transposition in disseminating tet(X3) between Acinetobacter species and elucidate the fitness changes employed by MDR strains under antibiotic selection pressures. Our study advocates the urgent need for surveillance of ISAba52-associated resistance elements in human, animal, and environmental settings.

1. Introduction

Tigecycline is the third-generation tetracycline antibiotic, acting as a last-resort approach to treat clinical MDR bacterial infections [1,2]. Since its first approval by the U.S. Food and Drug Administration (FDA) in 2015, tigecycline-resistant Gram-negative and Gram-positive bacteria have been inevitably detected worldwide [3,4,5]. The tigecycline resistance is usually conferred by bacterial efflux pumps and ribosomal protection proteins, including adeABC, tmexCD-toprJ, tet(A), tet(L), and tet(M) [6,7,8,9,10]. By contrast, the flavin-dependent monooxygenase Tet(X) can degrade all tetracycline antibiotics by hydroxylation, representing a unique enzymatic inactivation mechanism [11]. Recently, the rapid spread of the mobile tigecycline resistance gene tet(X3) has raised the concern that tigecycline may be clinically ineffective [12,13]. Thus far, the tet(X3) gene has been detected in Acinetobacter sp. isolates from various ecological niches in humans, food-producing animals, vegetables, soils, and water, especially in China [12,14,15]. Nevertheless, the horizontal transmission mechanism of tet(X3) in Acinetobacter spp. deserves further study.
The genus Acinetobacter is a heterogeneous group of Gram-negative bacteria, comprising 90 validly published species and more than 70 unnamed ones [16,17]. They are ubiquitous in nature but can also cause serious infections in hospital settings, including pneumonia, bloodstream infections, and wound infections [18,19,20,21]. In 2024, carbapenem-resistant Acinetobacter baumannii (CRAB) was classified as the critical group by the World Health Organization (WHO) Bacterial Priority Pathogens List [22]. Worrisomely, the tet(X3)-mediated tigecycline resistance and blaNDM-1-mediated carbapenem-resistance were simultaneously detected in A. baumannii, Acinetobacter indicus, Acinetobacter schindleri, Acinetobacter lwoffii, Acinetobacter johnsonii, Acinetobacter portensis, and Acinetobacter junii [12,14,23,24]. Although plasmid- and chromosome-borne tet(X3) genes have been reported, genetic environments indicated they were closely related to the insertion sequence ISCR2, possibly promoting the dissemination of multiple antibiotic resistance genes (ARGs) such as tet(X3), sul2, and floR [14,25]. On the other hand, the acquisition of ARGs usually leads to the fitness change of bacterial growth, competition, and biofilms, and antibiotics are important factors for adaptability, which remain poorly understood for tet(X3) [26,27,28].
As one of the strictly aerobic, oxidase-negative, and catalase-positive Acinetobacter species, A. amyesii has been reported in animal, soil, and water samples in the Czech Republic, Germany, Turkey, and Indonesia since its public report in 2022 [29,30]. In this study, we first reported an ISAba52-mediated transposon of tet(X3) between A. amyesii and A. baylyi in China by conjugation and high-throughput sequencing, and then explored the bacterial fitness by antimicrobial susceptibility, growth, competition, and biofilm experiments under the selection pressure of tigecycline, chlortetracycline, florfenicol, and trimethoprim-sulfamethoxazole.

2. Materials and Methods

2.1. Bacterial Strains and Ethical Statement

All procedures involving animal-derived isolates were approved by the Institutional Animal Care and Use Committee of Yangzhou University under the protocol number 202403072, following the relevant biosafety and ethical requirements. The tet(X3)-positive A. amyesii strain YH16040 was isolated from pig manure in 2016 in Jiangxi, China, derived from our previous multiregional study of tet(X)-mediated tigecycline-resistant Acinetobacter spp. [14]. A. baylyi ADP1, Escherichia coli C600, E. coli 25922, and Salmonella typhi ATCC 14028 are standard strains preserved in our laboratory.

2.2. Conjugation Experiments

The transferability of tet(X3)-mediated tigecycline resistance in A. amyesii YH16040 was determined by filter mating with rifampicin-resistant recipient strains A. baylyi ADP1, E. coli C600, and S. typhi ATCC 14028. After static incubation with the 0.22 μm pore-size filter membrane on Luria–Bertani (LB) agar plates at a donor/recipient ratio of 1/3 at 37 °C for 16 h, the mixture was resuspended in 1 mL LB broth. The putative transconjugants of them were all spread and selected on LB agar plates containing tigecycline (2 µg/mL) and rifampin (120 µg/mL), with tigecycline inhibiting the recipient strains and rifampicin inhibiting the donor strain in the bacterial mixture. Then they were screened for the target gene tet(X3) by PCR and confirmed by PCR-fingerprints for A. baylyi or enterobacterial repetitive intergenic consensus PCR (ERIC-PCR) for E. coli and S. typhi using genomic DNA as the templates [14]. Meanwhile, the recipient cells were spread and selected on LB agar plates containing rifampin (120 µg/mL). Transfer efficiency was calculated with mean ± standard deviation (SD) based on visual colony counts of the transconjugant and recipient cells [31].

2.3. Whole Genome Sequencing (WGS) and Bioinformatics Analyses

The bacterial genome was extracted using the TIANamp Bacteria DNA Kit (Tiangen, Beijing, China). To obtain the complete circular structures, WGS was performed by Illumina HiSeq and Oxford Nanopore sequencing (BENAGEN, Wuhan, China), followed by assembly with Unicycler version 0.5.0 and correction with Pilon version 1.24 [32,33]. Genome quality evaluation was conducted by QUAST version 5.2.0 and CheckM version 1.1.6, with the parameters of contigs (<300), N50 (>50 kb), completeness (>95%), contamination (<2%), and heterogeneity (<50%) [34,35]. Gene prediction and annotation were performed by Rapid Annotation using Subsystem Technology (RAST) version 2.0 [36]. Insertion sequences were analyzed by the online ISfinder platform [37]. The visual representation of the tet(X3)-related transposition process was generated with Easyfig version 2.2.5 [38]. Additionally, the 705 bp open reading frame (ORF) of ISAba52 of Acinetobacter spp. (taxid: 469) and E. coli (taxid: 562) deposited in the National Center for Biotechnology Information (NCBI) WGS and core_nt databases were collected by blastn, with a threshold of 100% nucleotide sequence similarity and coverage. Compared with the whole-genome sequences of Acinetobacter and E. coli type strains (https://lpsn.dsmz.de/, accessed on 10 November 2025), an average nucleotide identity (ANI) analysis was conducted using FastANI version 1.3 to define precise bacterial species by >95% [39].

2.4. Antimicrobial Susceptibility Testing

According to the U.S. Clinical and Laboratory Standards Institute (CLSI) guideline, minimum inhibitory concentrations (MICs) of chlortetracycline (0.125–256 μg/mL), tigecycline (0.015625–32 μg/mL), florfenicol (0.125–256 μg/mL), trimethoprim-sulfamethoxazole (1.25–320 μg/mL), CuSO4 (7.8125–2000 μg/mL), and CdCl2 (3.125–800 μg/mL) were determined by two-fold broth dilution in 200 μL Mueller–Hinton (MH) broth in 96-well plates at 37 °C for 24 h, respectively [40]. Particularly, the breakpoints of chlortetracycline, florfenicol, and trimethoprim-sulfamethoxazole were interpreted by CLSI, and that of tigecycline was interpreted by the FDA criterion for Enterobacteriaceae bacteria, which should be re-adjusted for MIC interpretation if the tigecycline resistance breakpoint for Acinetobacter spp. was established [14,40]. No clinical breakpoints were available for heavy metals CuSO4 and CdCl2. E. coli 25922 was used as the quality control strain.

2.5. Growth Curves

Suspensions of A. baylyi ADP1 and its transconjugant in the logarithmic growth phase were adjusted to a uniform concentration (OD600 = 0.1) for the determination of bacterial growth curves, respectively. After dilution with sterilized LB broth at a volume/volume ratio of 1/100, they were incubated with three different concentrations of tigecycline (0.015625, 0.125, and 1 μg/mL), chlortetracycline (0.125, 1, and 8 μg/mL), florfenicol (0.25, 1, and 4 μg/mL), or trimethoprim-sulfamethoxazole (0.625, 2.5, and 10 μg/mL) at 37 °C and 200 rpm for 16 h, and the antibiotic-untreated bacterial strains were used as blank controls. Particularly, the concentrations of four antibiotics were selected based on the results of MICs. OD600 was measured by Multifunctional Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA) at 0 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 16 h.

2.6. Competition Experiments

Suspensions of A. baylyi ADP1 and its transconjugant in the logarithmic growth phase (OD600 = 0.1) were mixed at a volume/volume ratio of 1/1, and then incubated with sub-inhibitory concentrations of tigecycline (0.015625 μg/mL), chlortetracycline (0.125 μg/mL), florfenicol (0.25 μg/mL), or trimethoprim-sulfamethoxazole (0.625 μg/mL) in LB broth at 37 °C and 200 rpm for 48 h. The antibiotic-untreated bacterial strains were used as blank controls. After a series of 10-fold dilutions, the transconjugant and A. baylyi ADP1 from the mixture were spread and selected by LB agar plates containing tigecycline (2 μg/mL) or not and confirmed by PCR amplification of the target gene tet(X3) using genomic DNA as the templates at 0 h, 24 h and 48 h, respectively [41]. As previously reported, the relative fitness (RF) was calculated with mean ± SD using the formula [RF = (log10S1dt − log10S1d0)/(log10S2dt − log10S2d0)] [42,43]. S1 and S2 represented visual colony-forming unit (CFU) densities of the transconjugant and A. baylyi ADP1, respectively. dt and d0 were the tested days. RF > 1 indicated that the transconjugant had a selective advantage over A. baylyi ADP1, whereas RF < 1 was defined as the bacterial fitness cost.

2.7. Crystal Violet Staining

After static incubation with three different concentrations of tigecycline (0.015625, 0.125, and 1 μg/mL), chlortetracycline (0.125, 1, and 8 μg/mL), florfenicol (0.25, 1, and 4 μg/mL), or trimethoprim-sulfamethoxazole (0.625, 2.5, and 10 μg/mL) in LB broth at 37 °C for 24 h, the bacterial suspension of A. baylyi ADP1 or its transconjugant was discarded. The antibiotic-untreated bacterial strains were used as blank controls. Next, the precipitation was washed three times with phosphate buffer saline (PBS), fixed in methanol for 15 min, stained with 0.1% crystal violet for 15 min, and then washed three times with PBS. Following the treatment of 95% ethanol for 15 min, OD570 was measured for the bacterial biofilm by Multifunctional Microplate Reader.

2.8. Statistical Analyses

All the bacterial conjugation, susceptibility, growth, competition, and biofilm experiments were performed in three biological replicates and repeated on at least two independent occasions. Statistical analyses were calculated by an unpaired and two-tailed t-test using GraphPad Prism version 8.3.0. Significant difference was defined as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; Not significant (NS), p ≥ 0.05.

3. Results

3.1. Transferability of tet(X3)-Mediated Tigecycline Resistance

In our previous national investigation, a tet(X3)-positive tigecycline-resistant Acinetobacter sp. YH16040 was isolated from a pig in 2016 in Jiangxi, China [14]. Here, it was re-designated as A. amyesii by ANI analysis with its type strain, namely A. amyesii ANC 5579 (GenBank accession number: GCA_023499985.1). MICs of A. amyesii YH16040 indicated that it was resistant to tigecycline (8 µg/mL), chlortetracycline (64 µg/mL), florfenicol (32 µg/mL), and trimethoprim-sulfamethoxazole (160 µg/mL) (Table 1). Successfully, the tet(X3) gene was transferred into the recipient A. baylyi ADP1 by conjugation at a frequency of (7.1 ± 2.5) × 10−8, suggesting its transferability. MIC results showed the obtained transconjugant YH16040C exhibited chlortetracycline resistance (64 μg/mL) and tigecycline resistance (8 μg/mL), together with the resistance to florfenicol (64 μg/mL) and trimethoprim-sulfamethoxazole (160 μg/mL), which increased by 64- to 256-fold compared with those of A. baylyi ADP1 (Table 1). However, there is no difference in MICs of heavy metals CuSO4 (500 μg/mL) or CdCl2 (12.5 μg/mL) between A. baylyi ADP1 and YH16040C (Table 1). On the other hand, the conjugation experiments with the recipient E. coli C600 and S. typhi ATCC 14028 failed despite multiple attempts, confirming that the genus Acinetobacter is a more appropriate bacterial host of tet(X3) than Enterobacteriaceae.

3.2. Transposition Mechanism of tet(X3) Across Acinetobacter Species

A. amyesii YH16040 carried a single combination of tigecycline resistance gene tet(X3), florfenicol resistance gene floR, trimethoprim-sulfamethoxazole resistance gene sul2, aminoglycoside resistance gene aph(3’)-la, and heavy metal tolerance genes (czcA, czcB, czcC, and czcD) on an 87.4 Kb GR31 circular plasmid (CP094542) [44]. WGS analyses of its transconjugant A. baylyi YH16040C were also conducted in this study. Genome quality met the requirements for the next analyses, such as the average depth (441×), contig (n = 1), N50 (3,833,693 kb), completeness (100%), contamination (0%), and heterogeneity (0%). Annotation results of the genetic environment revealed six ISAba52-mediated tandem repeats of tet(X3), floR, sul2, czcA, czcB, and czcC on the circular chromosome of YH16040C (CP186770), sharing >99.9% nucleotide identity and >99.9% nucleotide coverage. Presumably, a 35.9 Kb transposable unit from the donor A. amyesii YH16040 was inserted into the chromosome-derived fimbria/pilus outer membrane usher gene of A. baylyi ADP1 (NC_005966) six times; In addition, an ISAba52-mediated 15.4 Kb transposon of floR, czcA, czcB, and czcC was also found, resulting in the final 231.6 Kb complex transposon (Figure 1). GC content of the complex transposon (45.4%) was higher than that of the chromosome of A. baylyi ADP1 (40.4%). However, there was no significant additive effect on MICs of antibiotics or heavy metals between A. baylyi YH16040C and A. amyesii YH16040 (Table 1).
As described in the ISfinder database, ISAba52 belongs to the IS6 family and is 820 bp in length, containing an ORF from 64 bp to 768 bp and encoding a 234 aa transposase protein that shares 98% aa similarity to IS1006. Despite sporadic reports, results of the blastn query on 45,274 Acinetobacter genomes in the NCBI WGS database and 118,620,752 nucleotide sequences in the NCBI core_nt database further identified 781 non-duplicate bacterial strains carrying ISAba52, of which three isolates carried two copies each. For the bacterial species by ANI analyses, ISAba52 was widely distributed in 20 different Acinetobacter species (Table S1). The majority was A. baumannii (n = 688), followed by Acinetobacter nosocomialis (n = 22), A. amyesii (n = 15), A. indicus (n = 11), Acinetobacter pittii (n = 7), Acinetobacter towneri (n = 5), Taxon 76 (n = 5), Acinetobacter pseudolwoffii (n = 5), Acinetobacter ursingii (n = 4), A. johnsonii (n = 4), Acinetobacter bereziniae (n = 2), A. schindleri (n = 2), Acinetobacter variabilis (n = 2), Acinetobacter yuyunsongii (n = 2), Taxon 58 (n = 2), A. lwoffii (n = 1), Acinetobacter faecalis (n = 1), Candidatus Acinetobacter avistercoris (n = 1), Taxon 83 (n = 1), and novel Taxon 96 (n = 1). However, none was detected in 337,799 E. coli genomes in the NCBI WGS database and 118,620,752 nucleotide sequences in the NCBI core_nt database.

3.3. Fitness Effect of ISAba52-Mediated tet(X3) Transposon

3.3.1. Bacterial Growth

To explore the growth effect of ISAba52-mediated tet(X3) transposon, growth curves of A. baylyi ADP1 and its transconjugant YH16040C were determined under different concentrations of tigecycline, chlortetracycline, florfenicol, and trimethoprim-sulfamethoxazole, respectively (Figure 2). After four hours of co-culture, most of the tested strains rapidly proliferated except ADP1 inhibited by relatively high concentrations. In a blank control, YH16040C exhibited a significantly higher growth advantage than that of ADP1 at 16 h (p = 0.0268). Following incubation with a low dose of tigecycline (0.015625 μg/mL, p = 0.3929), florfenicol (0.25 μg/mL, p = 0.7018), or trimethoprim-sulfamethoxazole (0.625 μg/mL, p = 0.0498; 2.5 μg/mL, p = 0.1722), the growth rate of ADP1 reached that of YH16040C at 16 h. With the concentration increased, the growth advantage of YH16040C was all significantly higher than that of ADP1 at 16 h (p < 0.0001). These data showed that bacterial strains obtaining the ISAba52-mediated tet(X3) transposon have a growth advantage, especially under moderate antibiotic treatment.

3.3.2. Bacterial Competition

Furthermore, the competitive differentiation between A. baylyi ADP1 and YH16040C under the treatment of four antibiotics was analyzed (Figure 3). In the absence of antibiotics, YH16040C has a fitness cost compared to A. baylyi ADP1 (RF < 1). With the extension of incubation time, the fitness cost at 48 h (RF = 0.58 ± 0.09) was alleviated compared to that at 24 h (RF = 0.29 ± 0.02). Under the incubation of tigecycline (0.015625 μg/mL), YH16040C had a higher fitness advantage at 48 h (RF = 1.24 ± 0.11) than that at 24 h (RF = 1.13 ± 0.08). For chlortetracycline (0.125 μg/mL), it exhibited a similar advantage at 24 h (RF = 1.17 ± 0.13) but lost it at 48 h (RF = 0.85 ± 0.11). However, with the addition of florfenicol (0.25 μg/mL) or trimethoprim-sulfamethoxazole (0.625 μg/mL), YH16040C had a fitness cost at both 24 h and 48 h, with RF values ranging from 0.52 ± 0.1 to 0.83 ± 0.1.
At 24 h, all of tigecycline (p = 0.0001), chlortetracycline (p = 0.0007), florfenicol (p = 0.0019), and trimethoprim-sulfamethoxazole (p < 0.0001) were significantly beneficial for the competition ability of A. baylyi YH16040C carrying ISAba52-mediated tet(X3) transposon than that without antibiotics. At 48 h, only tigecycline (p = 0.0026) was significantly beneficial, while chlortetracycline (p = 0.0533), florfenicol (p = 0.6044), and trimethoprim-sulfamethoxazole (p = 0.1161) were not. The results indicated that antibiotics, even at low concentrations, may promote the competition ability of bacterial strains with transposons of tet(X3), especially tigecycline.

3.3.3. Bacterial Biofilm

In addition, the bacterial biofilm was successfully determined by the crystal violet staining method under different antibiotic selection pressure, resulting in complex phenotypic changes (Figure 4). Initially, there was no significant difference in biofilm formation between A. baylyi ADP1 and YH16040C in the absence of antibiotics (p ≥ 0.05). Under the induction of antibiotics, the biofilm of YH16040C was significantly lower than that of ADP1 at an appropriate concentration of tigecycline (0.015625 μg/mL, p = 0.0336) or chlortetracycline (0.125 μg/mL, p = 0.0364), while YH16040C was significantly higher than ADP1 at 4 μg/mL of florfenicol (p = 0.0494). With the addition of trimethoprim-sulfamethoxazole, the biofilm formation of YH16040C exhibited no significant change (p ≥ 0.05) compared to ADP1 under equivalent concentration conditions.

4. Discussion

To the best of our knowledge, tet(X3) is a unique tigecycline resistance gene in Acinetobacter sp. bacteria from human, animal, and environmental samples [15,45]. Previous studies showed that it was usually associated with ISCR2, which is an IS91-like element that lacks the inverted repeat sequences of most IS elements, and was located in a mobile transposon designed as ISCR2-tpnF-tet(X3)-hp-hp-ISCR2 [14,46]. In this study, we first reported an ISAba52-mediated transposition of tet(X3) between A. amyesii and A. baylyi. In silico analysis also revealed ISAba52 was widely distributed but restricted in Acinetobacter species, including A. baumannii, A. nosocomialis, A. amyesii, A. indicus, A. pittii, A. towneri, A. pseudolwoffii, A. ursingii, A. johnsonii, A. bereziniae, A. schindleri, A. variabilis, A. yuyunsongii, A. lwoffii, A. faecalis, Candidatus A. avistercoris, and four undefined species (namely Taxon 58, Taxon 76, Taxon 83, and Taxon 96). All these data indicate there is a risk of horizontal transmission of ISAba52-mediated tet(X3) gene in Acinetobacter species, which was underestimated previously, and tigecycline resistance monitoring and control are urgently needed following the international consensus of One Health.
Since the first report in 2019 in China, multiple copies of tet(X3) tandem structures have been detected in A. baumannii, A. indicus, A. pseudolwoffii, A. variabilis, and A. schindleri [12,14,44,47]. It is noted that tet(X3) and tet(X6) were also simultaneously detected in multiple Acinetobacter species, such as A. indicus, A. pseudolwoffii, A. schindleri, A. towneri, A. amyesii, A. lwoffii, and A. variabilis [14,15,23,48]. Here, we reported six ISAba52-mediated tandem repeats of ARGs tet(X3), floR, and sul2 on the chromosome of transconjugant A. baylyi YH16040C. However, there was no significant additive effect on MICs of tigecycline, chlortetracycline, florfenicol, or trimethoprim-sulfamethoxazole between A. baylyi YH16040C and its donor A. amyesii YH16040, which was consistent with our previous study on cloning of tet(X3) and tet(X6) [14]. Many studies indicated the tandem amplification was primarily achieved through complex gene rearrangements mediated by insertion sequence (IS), leading to an increase in the copy number of resistance genes and thereby forming heterogeneous resistant subpopulations among cells [49,50,51]. The molecular mechanism underlying the tet(X3), floR, and sul2 redundancy may be explained by the high propensity of Acinetobacter species to acquire tet(X3), floR, and sul2 genes by ISAba52, and remains to be further studied.
Acquired antibiotic resistance will provide adequate protection in the antibiotic environment, which may also cause bacterial metabolic burden and fitness cost if antibiotic use is inhibited [52,53]. After incubation in the blank medium, the relative fitness of A. baumannii obtaining a tet(X3)-positive plasmid or E. coli and K. pneumoniae obtaining a tet(X4)-positive plasmid was approximately 0.7–0.8 [12]. With the addition of different concentrations of L-arabinose, the fitness cost of E. coli or Salmonella Enteritidis carrying an arabinose-inducible plasmid pBAD-tet(X6) was significantly higher than that of Proteus mirabilis [54]. In this study, the capture of ISAba52-mediated tet(X3) in A. baylyi YH16040C led to a growth benefit, reduced competition ability, and non-significant difference in biofilm formation compared to A. baylyi ADP1 in the absence of antibiotics. The reduced competition ability despite growth benefits can be attributed to several factors. First, trade-offs between the growth rate and other fitness traits may occur, where the rapid growth compromises the competition ability [55]. Second, metabolic costs associated with growth-enhancing adaptations may divert resources from competition functions [56]. Third, environmental factors like nutrient limitation or spatial structure can decouple growth rates from competitive outcomes [57]. Apparently, the balance between benefits and fitness costs ultimately determines bacterial survival and evolutionary trajectories across diverse ecosystems.
A low dose of clinical antibiotics is often detected in humans, animals, and natural environments, representing an important risk factor affecting bacterial survival [58,59,60,61]. As previously reported, the specific resistance mechanism of tetracyclines was selected by each antibiotic generation [62]. The adaptability of A. baumannii under sub-MIC pressure of tigecycline was closely associated with a resistance-nodulation-division (RND) efflux pump AdeABC [8]. At present, we explored the effect of tetracyclines (chlortetracycline, tigecycline), phenicols (florfenicol), and sulphonamides (trimethoprim-sulfamethoxazole) on bacterial fitness. Under moderate antibiotic treatment, the competition ability of A. baylyi YH16040C against A. baylyi ADP1 was significantly higher than that without antibiotics, suggesting antibiotics promote the spread of tet(X)-positive Acinetobacter sp. strains. Although tigecycline is only approved to be used in human infections, tetracycline, florfenicol, and trimethoprim-sulfamethoxazole are largely utilized for animal production and human health [63,64]. Inevitably, Acinetobacter spp. carrying tet(X) genes exhibited multidrug resistance to the commonly used quinolone (e.g., ciprofloxacin) and carbapenem (e.g., meropenem) antibiotics, which contributed to their further spread [14,24,44]. In addition, heavy metals are also important environmental contaminants for co-selection of antibiotic resistance [65,66]. But the tolerance genes found in this study did not mediate the phenotype, which is worth further exploration. Therefore, limiting the use of antibiotics is critical in controlling the emergence and spread of multiple antimicrobial resistance in Acinetobacter sp. pathogens.

5. Conclusions

This study elucidated the transposition mechanism and fitness effect of mobile tet(X3) in Acinetobacter species. We identified the first ISAba52-mediated transposon harboring tet(X3), floR, and sul2 in A. amyesii, which exhibited efficient horizontal transferability into A. baylyi via conjugation. The transconjugant displayed elevated resistance to tigecycline, chlortetracycline, florfenicol, and trimethoprim-sulfamethoxazole, driven by tandem ISAba52 repeats forming a complex transposable unit. Antibiotic-dependent advantages of tet(X3)-harboring bacteria outcompeting tet(X3)-negative parental strains was revealed under moderate antibiotic treatment. These findings highlight the role of ISAba52-mediated transposition in disseminating tet(X3) and the potential fitness changes of Acinetobacter spp. due to antibiotic selection. Surveillance of such elements is critical to mitigate the spread of multidrug resistance in human, animal, and environmental settings.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms13122656/s1, Table S1: ANI-based Acinetobacter species carrying ISAba52.

Author Contributions

Conceptualization, J.H. and C.C.; methodology, C.C.; formal analysis, J.L., J.G. and Y.H.; data curation, J.L., J.G., Y.H. and T.W.; writing—original draft preparation, C.C. and J.L.; writing—review and editing, C.C.; visualization, J.L. and J.G.; project administration, J.H.; funding acquisition, J.H. and C.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Key Research and Development Program of China (grant number 2024YFC2310300), the National Natural Science Foundation of China (grant number 32402890), and the China Postdoctoral Science Foundation (grant number 2023M732993).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
MDRMultidrug-resistant
FDAFood and Drug Administration
CRABCarbapenem-resistant Acinetobacter baumannii
WHOWorld Health Organization
ARGsAntibiotic resistance genes
LBLuria–Bertani
ERIC-PCREnterobacterial repetitive intergenic consensus PCR
SDStandard deviation
WGSWhole genome sequencing
RASTRapid annotation using subsystem technology
ORFOpen reading frame
NCBINational Center for Biotechnology Information
ANIAverage nucleotide identity
CLSIClinical and Laboratory Standards Institute
MICsMinimum inhibitory concentrations
MHMueller–Hinton
RFRelative fitness
CFUColony-forming unit
PBSPhosphate buffer saline
NSNot significant
ISInsertion sequence
RNDResistance-nodulation-division

References

  1. Seifert, H.; Blondeau, J.; Lucassen, K.; Utt, E.A. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016–2018). J. Glob. Antimicrob. Resist. 2022, 31, 82–89. [Google Scholar] [CrossRef] [PubMed]
  2. Huang, Y.-S.; Yang, J.-L.; Wang, J.-T.; Sheng, W.-H.; Yang, C.-J.; Chuang, Y.-C.; Chang, S.-C. Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae. J. Infect. Public Health 2024, 17, 929–937. [Google Scholar] [CrossRef] [PubMed]
  3. Hua, X.; He, J.; Wang, J.; Zhang, L.; Zhang, L.; Xu, Q.; Shi, K.; Leptihn, S.; Shi, Y.; Fu, X.; et al. Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf. Emerg. Microbes Infect. 2021, 10, 1404–1417. [Google Scholar] [CrossRef]
  4. Anyanwu, M.U.; Nwobi, O.C.; Okpala, C.O.R.; Ezeonu, I.M. Mobile Tigecycline Resistance: An Emerging Health Catastrophe Requiring Urgent One Health Global Intervention. Front. Microbiol. 2022, 13, 808744. [Google Scholar] [CrossRef]
  5. Shariati, A.; Dadashi, M.; Chegini, Z.; van Belkum, A.; Mirzaii, M.; Khoramrooz, S.S.; Darban-Sarokhalil, D. The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase–negative staphylococci strains: A systematic review and meta-analysis. Antimicrob. Resist. Infect. Control. 2020, 9, 56. [Google Scholar] [CrossRef] [PubMed]
  6. Lv, L.; Wan, M.; Wang, C.; Gao, X.; Yang, Q.; Partridge, S.R.; Wang, Y.; Zong, Z.; Doi, Y.; Shen, J.; et al. Emergence of a Plasmid-Encoded Resistance-Nodulation-Division Efflux Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in Klebsiella pneumoniae. mBio 2020, 11, e02930-19. [Google Scholar] [CrossRef]
  7. Chiu, S.K.; Huang, L.Y.; Chen, H.; Tsai, Y.K.; Liou, C.H.; Lin, J.C.; Siu, L.K.; Chang, F.Y.; Yeh, K.M. Roles of ramR and tet(A) Mutations in Conferring Tigecycline Resistance in Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates. Antimicrob. Agents Chemother. 2017, 61, e00391-17. [Google Scholar] [CrossRef]
  8. Liu, C.; Liu, J.; Lu, Q.; Wang, P.; Zou, Q. The Mechanism of Tigecycline Resistance in Acinetobacter baumannii under Sub-Minimal Inhibitory Concentrations of Tigecycline. Int. J. Mol. Sci. 2024, 25, 1819. [Google Scholar] [CrossRef]
  9. Yu, R.; Zhang, Y.; Xu, Y.; Schwarz, S.; Li, X.-S.; Shang, Y.-H.; Du, X.-D. Emergence of a tet(M) Variant Conferring Resistance to Tigecycline in Streptococcus suis. Front. Vet. Sci. 2021, 8, 709327. [Google Scholar] [CrossRef]
  10. Brajerova, M.; Nyc, O.; Drevinek, P.; Krutova, M. Genomic insights into the spread of vancomycin- and tigecycline-resistant Enterococcus faecium ST117. Ann. Clin. Microb. Antimicrob. 2025, 24, 36. [Google Scholar] [CrossRef]
  11. Yao, C.; Jin, L.; Wang, Q.; Wang, M.; Wang, R.; Cai, M.; Song, K.; Wang, H. Unraveling the evolution and global transmission of high level tigecycline resistance gene tet(X). Environ. Int. 2025, 199, 109499. [Google Scholar] [CrossRef] [PubMed]
  12. He, T.; Wang, R.; Liu, D.J.; Walsh, T.R.; Zhang, R.; Lv, Y.; Ke, Y.B.; Ji, Q.J.; Wei, R.C.; Liu, Z.H.; et al. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat. Microbiol. 2019, 4, 1450–1456. [Google Scholar] [CrossRef] [PubMed]
  13. Cao, J.; Wang, J.; Wang, Y.; Wang, L.; Bi, Y.; Zhu, B.; Gao, G.F. Tigecycline resistance tet(X3) gene is going wild. Biosaf. Health 2020, 2, 9–11. [Google Scholar] [CrossRef]
  14. Chen, C.; Cui, C.Y.; Yu, J.J.; He, Q.; Wu, X.T.; He, Y.Z.; Cui, Z.H.; Li, C.; Jia, Q.L.; Shen, X.G.; et al. Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species. Genome Med. 2020, 12, 111. [Google Scholar] [CrossRef]
  15. Chen, C.; Wu, T.; Liu, J.; Gao, J. Threat and Control of tet(X)-Mediated Tigecycline-Resistant Acinetobacter sp. Bacteria. Foods 2025, 14, 3374. [Google Scholar] [CrossRef]
  16. Qin, J.; Feng, Y.; Lu, X.; Zong, Z. Precise Species Identification for Acinetobacter: A Genome-Based Study with Description of Two Novel Acinetobacter Species. mSystems 2021, 6, e00237-21. [Google Scholar] [CrossRef]
  17. Freese, H.M.; Meier-Kolthoff, J.P.; Sardà Carbasse, J.; O. Afolayan, A.; Göker, M. TYGS and LPSN in 2025: A Global Core Biodata Resource for genome-based classification and nomenclature of prokaryotes within DSMZ Digital Diversity. Nucleic Acids Res. 2025; Online ahead of print. [Google Scholar] [CrossRef]
  18. Al Atrouni, A.; Joly-Guillou, M.L.; Hamze, M.; Kempf, M. Reservoirs of Non-baumannii Acinetobacter Species. Front. Microbiol. 2016, 7, 49. [Google Scholar] [CrossRef]
  19. Wong, D.; Nielsen, T.B.; Bonomo, R.A.; Pantapalangkoor, P.; Luna, B.; Spellberg, B. Clinical and Pathophysiological Overview of Acinetobacter Infections: A Century of Challenges. Clin. Microbiol. Rev. 2017, 30, 409–447. [Google Scholar] [CrossRef]
  20. Luo, Q.; Chang, M.; Lu, P.; Guo, Q.; Jiang, X.; Xiao, T.; Zhang, H.; Ma, Y.; Zhang, Y.; Yu, W.; et al. Genomic epidemiology and phylodynamics of Acinetobacter baumannii bloodstream isolates in China. Nat. Commun. 2025, 16, 3536. [Google Scholar] [CrossRef] [PubMed]
  21. Mohd Sazlly Lim, S.; Zainal Abidin, A.; Liew, S.M.; Roberts, J.A.; Sime, F.B. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis. J. Infect. 2019, 79, 593–600. [Google Scholar] [CrossRef]
  22. WHO. WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. Available online: https://www.who.int/publications/i/item/9789240093461 (accessed on 30 September 2025).
  23. Cui, C.Y.; Chen, C.; Liu, B.T.; He, Q.; Wu, X.T.; Sun, R.Y.; Zhang, Y.; Cui, Z.H.; Guo, W.Y.; Jia, Q.L.; et al. Co-occurrence of Plasmid-Mediated Tigecycline and Carbapenem Resistance in Acinetobacter spp. from Waterfowls and Their Neighboring Environment. Antimicrob. Agents Chemother. 2020, 64, e02502-19. [Google Scholar] [CrossRef]
  24. Li, X.; Zhuang, Y.; Yu, Y.; Jia, H.; Kong, Y.; Zhang, J.; Xie, X.; Stehling, E.G.; Furlan, J.P.R.; Zhou, Z.; et al. Interplay of multiple carbapenemases and tigecycline resistance in Acinetobacter species: A serious combined threat. Clin. Microbiol. Infect. 2025, 31, 128–133. [Google Scholar] [CrossRef]
  25. Montaña, S.; Almuzara, M.; Pennini, M.; Sucari, A.; Centrón, D.; Vay, C.A.; Ramírez, M.S. ISCR2 and IS26: Two Insertion Sequences Highly Dispersed among Acinetobacter spp. Clinical Strains. J. Bacteriol. Mycol. Open Access 2017, 4, 33–36. [Google Scholar] [CrossRef]
  26. Yaffe, E.; Dethlefsen, L.; Patankar, A.V.; Gui, C.; Holmes, S.; Relman, D.A. Brief antibiotic use drives human gut bacteria towards low-cost resistance. Nature 2025, 641, 182–191. [Google Scholar] [CrossRef]
  27. Guo, Z.; Feng, S.; Liang, L.; Wu, Z.; Min, L.; Wang, R.; Li, J.; Zhong, L.-L.; Zhao, H.; Chen, X.; et al. Assessment of the reversibility of resistance in the absence of antibiotics and its relationship with the resistance gene’s fitness cost: A genetic study with mcr-1. Lancet Microbe 2024, 5, 100846. [Google Scholar] [CrossRef] [PubMed]
  28. Tu, M.M.; Carfrae, L.A.; Rachwalski, K.; French, S.; Catacutan, D.; Gordzevich, R.; MacNair, C.R.; Speagle, M.E.; Werah, F.; Stokes, J.M.; et al. Exploiting the fitness cost of metallo-β-lactamase expression can overcome antibiotic resistance in bacterial pathogens. Nat. Microbiol. 2025, 10, 53–65. [Google Scholar] [CrossRef]
  29. Nemec, A.; Radolfová-Křížová, L.; Maixnerová, M.; Nemec, M.; Shestivska, V.; Španělová, P.; Kyselková, M.; Wilharm, G.; Higgins, P.G. Acinetobacter amyesii sp. nov., widespread in the soil and water environment and animals. Int. J. Syst. Evol. Microbiol. 2022, 72, 005642. [Google Scholar] [CrossRef] [PubMed]
  30. Dede, A.; Pérez-Valera, E.; Elhottová, D. Genome analysis of manure and soil-dwelling Acinetobacter strains indicates potential health risks associated with antibiotic resistance and virulence factors. Microb. Pathog. 2025, 205, 107610. [Google Scholar] [CrossRef] [PubMed]
  31. Zhu, W.; Clark, N.; Patel, J.B. pSK41-like plasmid is necessary for Inc18-like vanA plasmid transfer from Enterococcus faecalis to Staphylococcus aureus in vitro. Antimicrob. Agents Chemother. 2013, 57, 212–219. [Google Scholar] [CrossRef]
  32. Wick, R.R.; Judd, L.M.; Gorrie, C.L.; Holt, K.E. Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput. Biol. 2017, 13, e1005595. [Google Scholar] [CrossRef]
  33. Walker, B.J.; Abeel, T.; Shea, T.; Priest, M.; Abouelliel, A.; Sakthikumar, S.; Cuomo, C.A.; Zeng, Q.; Wortman, J.; Young, S.K.; et al. Pilon: An integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS ONE 2014, 9, e112963. [Google Scholar] [CrossRef] [PubMed]
  34. Gurevich, A.; Saveliev, V.; Vyahhi, N.; Tesler, G. QUAST: Quality assessment tool for genome assemblies. Bioinformatics 2013, 29, 1072–1075. [Google Scholar] [CrossRef]
  35. Parks, D.H.; Imelfort, M.; Skennerton, C.T.; Hugenholtz, P.; Tyson, G.W. CheckM: Assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res. 2015, 25, 1043–1055. [Google Scholar] [CrossRef]
  36. Aziz, R.K.; Bartels, D.; Best, A.A.; DeJongh, M.; Disz, T.; Edwards, R.A.; Formsma, K.; Gerdes, S.; Glass, E.M.; Kubal, M.; et al. The RAST Server: Rapid annotations using subsystems technology. BMC Genom. 2008, 9, 75. [Google Scholar] [CrossRef]
  37. Siguier, P. ISfinder: The reference centre for bacterial insertion sequences. Nucleic Acids Res. 2006, 34, D32–D36. [Google Scholar] [CrossRef]
  38. Sullivan, M.J.; Petty, N.K.; Beatson, S.A. Easyfig: A genome comparison visualizer. Bioinformatics 2011, 27, 1009–1010. [Google Scholar] [CrossRef]
  39. Jain, C.; Rodriguez-R, L.M.; Phillippy, A.M.; Konstantinidis, K.T.; Aluru, S. High throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries. Nat. Commun. 2018, 9, 5114. [Google Scholar] [CrossRef]
  40. CLSI M100-Ed32; CLSI Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2022.
  41. Ji, K.; Xu, Y.; Sun, J.; Huang, M.; Jia, X.; Jiang, C.; Feng, Y. Harnessing efficient multiplex PCR methods to detect the expanding Tet(X) family of tigecycline resistance genes. Virulence 2019, 11, 49–56. [Google Scholar] [CrossRef] [PubMed]
  42. Wu, R.; Yi, L.X.; Yu, L.F.; Wang, J.; Liu, Y.; Chen, X.; Lv, L.; Yang, J.; Liu, J.H. Fitness Advantage of mcr-1-Bearing IncI2 and IncX4 Plasmids in Vitro. Front. Microbiol. 2018, 9, 331. [Google Scholar] [CrossRef] [PubMed]
  43. Machuca, J.; Briales, A.; Labrador, G.; Diaz-de-Alba, P.; Lopez-Rojas, R.; Docobo-Perez, F.; Martinez-Martinez, L.; Rodriguez-Bano, J.; Pachon, M.E.; Pascual, A.; et al. Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in Escherichia coli. J. Antimicrob. Chemother. 2014, 69, 3203–3215. [Google Scholar] [CrossRef] [PubMed]
  44. Chen, C.; Huang, P.-Y.; Cui, C.-Y.; He, Q.; Sun, J.; Liu, Y.-H.; Huang, J.-L. Classification and molecular characteristics of tet(X)-carrying plasmids in Acinetobacter species. Front. Microbiol. 2022, 13, 974432. [Google Scholar] [CrossRef]
  45. Zhang, R.-M.; Sun, J.; Sun, R.-Y.; Wang, M.-G.; Cui, C.-Y.; Fang, L.-X.; Liao, M.-N.; Lu, X.-Q.; Liu, Y.-X.; Liao, X.-P.; et al. Source Tracking and Global Distribution of the Tigecycline Non-Susceptible tet(X). Microbiol. Spectr. 2021, 9, e01164-21, Erratum in Microbiol. Spectr. 2022, 10, e01131-22. https://doi.org/10.1128/spectrum.01131-22. [Google Scholar] [CrossRef]
  46. Cheng, Y.Y.; Liu, Y.; Chen, Y.; Huang, F.M.; Chen, R.C.; Xiao, Y.H.; Zhou, K. Sporadic Dissemination of tet(X3) and tet(X6) Mediated by Highly Diverse Plasmidomes among Livestock-Associated Acinetobacter. Microbiol. Spectr. 2021, 9, e01141-21. [Google Scholar] [CrossRef]
  47. Cheng, Y.M.; Li, Y.K.; Yu, R.H.; Ma, M.X.; Yang, M.; Si, H.B. Identification of Novel tet(X3) Variants Resistant To Tigecycline in Acinetobacter Species. Microbiol. Spectr. 2022, 10, e01333-22. [Google Scholar] [CrossRef]
  48. Wang, J.; Lu, M.J.; Wu, H.; Wang, Z.Y.; Mei, C.Y.; Tian, Y.Q.; Pan, Z.M.; Jiao, X. Plasmid-borne tet(X3) and chromosome-borne tet(X6) in porcine Acinetobacter isolates. J. Glob. Antimicrob. Resist. 2022, 29, 17–19. [Google Scholar] [CrossRef]
  49. Wei, D.-W.; Wong, N.-K.; Song, Y.; Zhang, G.; Wang, C.; Li, J.; Feng, J.; Bonomo, R.A. IS26 Veers Genomic Plasticity and Genetic Rearrangement toward Carbapenem Hyperresistance under Sublethal Antibiotics. mBio 2022, 13, e03340-21, Erratum in mBio 2022, 13, e00414-22. https://doi.org/10.1128/mbio.00414-22. [Google Scholar] [CrossRef]
  50. Girgis, H.S.; DuPai, C.D.; Lund, J.; Reeder, J.; Guillory, J.; Durinck, S.; Liang, Y.; Kaminker, J.; Smith, P.A.; Skippington, E. Single-molecule nanopore sequencing reveals extreme target copy number heterogeneity in arylomycin-resistant mutants. Proc. Natl. Acad. Sci. USA 2020, 118, e2021958118. [Google Scholar] [CrossRef] [PubMed]
  51. Pal, A.; Andersson, D.I. Bacteria can compensate the fitness costs of amplified resistance genes via a bypass mechanism. Nat. Commun. 2024, 15, 2333. [Google Scholar] [CrossRef]
  52. Fuzi, M. The fitness connection of antibiotic resistance. Front. Microbiol. 2025, 16, 1556656. [Google Scholar] [CrossRef]
  53. Jo, J.; Kim, S.J.; Kwon, K.T.; Ko, K.S. Resilience of tigecycline heteroresistance phenotype in Acinetobacter baumannii. J. Antimicrob. Chemother. 2025, 80, 496–502. [Google Scholar] [CrossRef]
  54. Jiang, L.; Cai, W.; Tang, F.; Wang, Z.; Liu, Y. Characterization of Fitness Cost Caused by Tigecycline-Resistance Gene tet(X6) in Different Host Bacteria. Antibiotics 2021, 10, 1172. [Google Scholar] [CrossRef]
  55. Zhu, M.; Dai, X. Shaping of microbial phenotypes by trade-offs. Nat. Commun. 2024, 15, 4238. [Google Scholar] [CrossRef]
  56. Heilbronner, S.; Krismer, B.; Brötz-Oesterhelt, H.; Peschel, A. The microbiome-shaping roles of bacteriocins. Nat. Rev. Microbiol. 2021, 19, 726–739. [Google Scholar] [CrossRef]
  57. Batsch, M.; Guex, I.; Todorov, H.; Heiman, C.M.; Vacheron, J.; Vorholt, J.A.; Keel, C.; van der Meer, J.R. Fragmented micro-growth habitats present opportunities for alternative competitive outcomes. Nat. Commun. 2024, 15, 7591. [Google Scholar] [CrossRef]
  58. Liu, Y.; Zhang, M.; Wu, Y.; Li, S.; Hu, J.; Sun, W.; Ni, J. Profiles, drivers, and prioritization of antibiotics in China’s major rivers. J. Hazard. Mater. 2024, 477, 135399. [Google Scholar] [CrossRef] [PubMed]
  59. Wang, Q.; Duan, Y.J.; Wang, S.P.; Wang, L.T.; Hou, Z.L.; Cui, Y.X.; Hou, J.; Das, R.; Mao, D.Q.; Luo, Y. Occurrence and distribution of clinical and veterinary antibiotics in the faeces of a Chinese population. J. Hazard. Mater. 2019, 383, 121129. [Google Scholar] [CrossRef]
  60. Fu, Y.; Chen, Y.; Liu, D.; Yang, D.; Liu, Z.; Wang, Y.; Wang, J.; Wang, X.; Xu, X.; Li, X.; et al. Abundance of tigecycline resistance genes and association with antibiotic residues in Chinese livestock farms. J. Hazard. Mater. 2021, 409, 124921. [Google Scholar] [CrossRef]
  61. Wan, Y.P.; Liu, Z.H.; Liu, Y. Veterinary antibiotics in swine and cattle wastewaters of China and the United States: Features and differences. Water Environ. Res. 2021, 93, 1516–1529. [Google Scholar] [CrossRef] [PubMed]
  62. Blake, K.S.; Xue, Y.-P.; Gillespie, V.J.; Fishbein, S.R.S.; Tolia, N.H.; Wencewicz, T.A.; Dantas, G. The tetracycline resistome is shaped by selection for specific resistance mechanisms by each antibiotic generation. Nat. Commun. 2025, 16, 1452. [Google Scholar] [CrossRef] [PubMed]
  63. Klein, E.Y.; Impalli, I.; Poleon, S.; Denoel, P.; Cipriano, M.; Van Boeckel, T.P.; Pecetta, S.; Bloom, D.E.; Nandi, A. Global trends in antibiotic consumption during 2016–2023 and future projections through 2030. Proc. Natl. Acad. Sci. USA 2024, 121, e2411919121. [Google Scholar] [CrossRef] [PubMed]
  64. ECDC; EFSA; EMA. ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. EFSA J. 2017, 15, e04872. [Google Scholar] [CrossRef]
  65. Anedda, E.; Farrell, M.L.; Morris, D.; Burgess, C.M. Evaluating the impact of heavy metals on antimicrobial resistance in the primary food production environment: A scoping review. Environ. Pollut. 2023, 320, 121035. [Google Scholar] [CrossRef]
  66. Murray, L.M.; Hayes, A.; Snape, J.; Kasprzyk-Hordern, B.; Gaze, W.H.; Murray, A.K. Co-selection for antibiotic resistance by environmental contaminants. NPJ Antimicrob. Resist. 2024, 2, 9. [Google Scholar] [CrossRef] [PubMed]
Figure 1. ISAba52-mediated transposition of tet(X3) in Acinetobacter species. The target gene, mobile element, ARGs, heavy metal tolerance gene, and other genes are represented by green, blue, red, purple, and orange colors, respectively. Regions of >98% nucleotide identity are marked by shading.
Figure 1. ISAba52-mediated transposition of tet(X3) in Acinetobacter species. The target gene, mobile element, ARGs, heavy metal tolerance gene, and other genes are represented by green, blue, red, purple, and orange colors, respectively. Regions of >98% nucleotide identity are marked by shading.
Microorganisms 13 02656 g001
Figure 2. Bacterial growth curve. The growth curve under the selection pressure of tigecycline (A), chlortetracycline (B), florfenicol (C), and trimethoprim-sulfamethoxazole (D) is present, respectively. The A. baylyi strains YH16040C (transconjugant) and ADP1 (recipient) without antibiotics are used as the blank controls.
Figure 2. Bacterial growth curve. The growth curve under the selection pressure of tigecycline (A), chlortetracycline (B), florfenicol (C), and trimethoprim-sulfamethoxazole (D) is present, respectively. The A. baylyi strains YH16040C (transconjugant) and ADP1 (recipient) without antibiotics are used as the blank controls.
Microorganisms 13 02656 g002
Figure 3. Relative fitness under the selection of tigecycline, chlortetracycline, florfenicol, and trimethoprim-sulfamethoxazole. A. baylyi ADP1 and its transconjugant YH16040C without antibiotics are used as the blank controls. **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; NS, not significant, p ≥ 0.05.
Figure 3. Relative fitness under the selection of tigecycline, chlortetracycline, florfenicol, and trimethoprim-sulfamethoxazole. A. baylyi ADP1 and its transconjugant YH16040C without antibiotics are used as the blank controls. **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; NS, not significant, p ≥ 0.05.
Microorganisms 13 02656 g003
Figure 4. Bacterial biofilms. The biofilm under the selection pressure of tigecycline (A), chlortetracycline (B), florfenicol (C), and trimethoprim-sulfamethoxazole (D) is present, respectively. A. baylyi ADP1 and its transconjugant YH16040C, grown without antibiotics, serve as the blank controls. *, p < 0.05; NS, not significant, p ≥ 0.05.
Figure 4. Bacterial biofilms. The biofilm under the selection pressure of tigecycline (A), chlortetracycline (B), florfenicol (C), and trimethoprim-sulfamethoxazole (D) is present, respectively. A. baylyi ADP1 and its transconjugant YH16040C, grown without antibiotics, serve as the blank controls. *, p < 0.05; NS, not significant, p ≥ 0.05.
Microorganisms 13 02656 g004
Table 1. MICs of the tetracyclines, phenicols, sulfonamides, and heavy metals (μg/mL).
Table 1. MICs of the tetracyclines, phenicols, sulfonamides, and heavy metals (μg/mL).
StrainsTigecyclineChlortetracyclineFlorfenicolTrimethoprim-Sulfamethoxazole aCuSO4CdCl2
A. amyesii YH160408643216050012.5
A. baylyi YH16040C8646416050012.5
A. baylyi ADP10.031250.2512.550012.5
a Trimethoprim and sulfamethoxazole are mixed at a ratio of 1/19 before two-fold broth dilution.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chen, C.; Liu, J.; Gao, J.; Hua, Y.; Wu, T.; Huang, J. Transfer and Fitness of ISAba52-Mediated tet(X3) Transposon in Acinetobacter spp. Microorganisms 2025, 13, 2656. https://doi.org/10.3390/microorganisms13122656

AMA Style

Chen C, Liu J, Gao J, Hua Y, Wu T, Huang J. Transfer and Fitness of ISAba52-Mediated tet(X3) Transposon in Acinetobacter spp. Microorganisms. 2025; 13(12):2656. https://doi.org/10.3390/microorganisms13122656

Chicago/Turabian Style

Chen, Chong, Jing Liu, Jie Gao, Yubing Hua, Taotao Wu, and Jinlin Huang. 2025. "Transfer and Fitness of ISAba52-Mediated tet(X3) Transposon in Acinetobacter spp." Microorganisms 13, no. 12: 2656. https://doi.org/10.3390/microorganisms13122656

APA Style

Chen, C., Liu, J., Gao, J., Hua, Y., Wu, T., & Huang, J. (2025). Transfer and Fitness of ISAba52-Mediated tet(X3) Transposon in Acinetobacter spp. Microorganisms, 13(12), 2656. https://doi.org/10.3390/microorganisms13122656

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop